BIOMARIN PHARMACEUTICAL INC

BioMarin Pharmaceutical Inc. develops and commercializes therapies targeting serious genetic conditions and rare diseases. The biotechnology company organizes its commercial operations into two core business units: Skeletal Conditions and Enzyme Therapies. Key commercial products include VOXZOGO for achondroplasia, alongside enzyme replacement treatments such as VIMIZIM, NAGLAZYME, PALYNZIQ, ALDURAZYME, BRINEURA, and KUVAN. Its customer base consists of specialty pharmacies, hospitals, non-U.S. government entities, pharmaceutical wholesalers, and authorized international distributors, with Sanofi acting as the exclusive distributor and customer for ALDURAZYME.

The company operates globally, conducting direct sales in the United States, Europe, and South America, while serving additional international territories through third-party distribution partners. Its manufacturing infrastructure includes specialized production facilities located in Novato, California, and Shanbally, Cork, Ireland, supplemented by external contract manufacturing organizations. BioMarin Pharmaceutical Inc. maintains its corporate headquarters in San Rafael, California.

Summary of the business section of Biomarin Pharmaceutical's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 3,221 employees worldwide, of whom 1,518 were in operations, 692 were in research and development, 495 were in sales and marketing and 516 were in administration.”